An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
BELLUS Health Inc. (Nasdaq: BLU), a clinical-stage biopharmaceutical company, will participate in the Cowen & Co. 42nd Annual Health Care Conference. CEO Roberto Bellini will be on the Respiratory/Infections Panel on March 8, 2022, at 2:10 p.m. ET. The panel discussion will address the company's advancements in treating refractory chronic cough (RCC) and other cough hypersensitivity conditions. Following the event, a recorded webcast will be available on BELLUS Health's website. This aligns with their goal to initiate a Phase 3 program for their product candidate BLU-5937 in late 2022.
Positive
None.
Negative
None.
LAVAL, Quebec--(BUSINESS WIRE)--
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a panel at the Cowen & Co. 42nd Annual Health Care Conference.
Panel Details:
Event: Cowen & Co. 42nd Annual Health Care Conference Title:Respiratory/Infections Panel Date/Time: Tuesday, March 8th, 2022 at 2:10 p.m. ET
A webcast of the panel discussion may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
When is BELLUS Health participating in the Cowen & Co. conference?
BELLUS Health will participate in the Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET.
Who is representing BELLUS Health at the Cowen & Co. conference?
CEO Roberto Bellini will represent BELLUS Health at the conference.
What is the focus of the panel discussion at the Cowen & Co. conference?
The panel discussion will focus on respiratory and infection-related topics, including developments in refractory chronic cough treatments.
What is refractory chronic cough (RCC)?
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying conditions, affecting approximately 9 million patients in the United States.
What is the status of BELLUS Health's product candidate BLU-5937?
BLU-5937 has successfully completed a Phase 2b trial for RCC, and a Phase 3 program is expected to begin in the second half of 2022.
